3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Neoplasm Metastasis
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Breast Diseases
1
Interventions
pembrolizumab
33
Docetaxel
10
Nivolumab
9
Paclitaxel
6
Trastuzumab
5
Gemcitabine
5
Cetuximab
5
Carboplatin
5
Capecitabine
5
Fulvestrant
4
Cyclophosphamide
4
spartalizumab
3
poly ICLC
3
durvalumab
3
avelumab
3
Oxaliplatin
3
Leucovorin
3
Ipilimumab
3
Fluorouracil
3
Cisplatin
3
Biopsy
3
zimberelimab
2
tremelimumab
2
palbociclib
2
obinutuzumab
2
lenvatinib
2
cemiplimab
2
budigalimab
2
Vorinostat
2
Specimen Handling
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Squamous Cell Carcinoma of Head and Neck
×
STX-478
×
Breast
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled